A real-world experience with a thin-strut bioresorbable vascular scaffold system: a single-centre study

Despite the significant advancements in interventional cardiology, there is a need for new, metal-free bioresorbable stent systems that preserve the vasomotor function of the treated vessel and decrease the risk of restenosis associated with metal stents and the risk of thrombosis associated with first-generation bioresorbable scaffolds.

The aim of this study was to assess the safety and efficacy of the MeRes100 bioresorbable scaffold in complex de novo and in-stent restenotic coronary lesions.

We conducted a retrospective single-centre study that included 86 patients with coronary artery disease who had been implanted with a next-generation MeRes100 sirolimus-eluting bioresorbable vascular scaffold system and followed up to 12 months after the procedure.

The scaffold was successfully delivered to the target lesion with satisfactory stent expansion in 98.84% of cases. Only one patient died, and the in-hospital mortality rate was as low as 1.16% (cardiac death). No cases of major adverse cardiac events, cardiac death, myocardial infarction, ischaemia-driven target lesion revascularisation, or scaffold thrombosis were reported during the follow-up.

Our preliminary data suggest that the thin-strut sirolimus-eluting bioresorbable scaffold appears to be a clinically acceptable, safe, reliable and reproducible strategy to treat both de novo and in-stent restenotic coronary artery lesions. Long-term follow-up of a larger patient population is warranted.